ロード中...

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017

IMPORTANCE: Sipuleucel-T was the first therapeutic cancer vaccine approved by the US Food and Drug Administration (FDA) in 2010. Although almost a decade has passed since its approval for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC), there remain...

詳細記述

保存先:
書誌詳細
出版年:JAMA Netw Open
主要な著者: Dores, Graça M., Bryant-Genevier, Marthe, Perez-Vilar, Silvia
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694390/
https://ncbi.nlm.nih.gov/pubmed/31411714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.9249
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!